AZN R&D to Revenue
AstraZeneca PLC Ordinary Shares · R&D to Revenue
AZN R&D to Revenue
Latest reported24.23%period ending
AZN FY R&D/Revenue (9.58% → 24.23%)
Latest values, visible window
High-resolution chart · PNG
AZN r&d to revenue history
Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 24.2292% | |
| 22.5954% | |
| 22.5819% | |
| 21.7334% | |
| 22.5914% | |
| 22.0845% | |
| 21.8176% | |
| 23.8388% | |
| 24.0908% | |
| 24.4805% | |
| 22.6769% | |
| 18.6123% | |
| 16.5338% | |
| 15.161% | |
| 13.4143% | |
| 12.3027% | |
| 12.9283% | |
| 15.3761% | |
| 17.2164% | |
| 14.6742% | |
| 14.1086% | |
| 16.1813% | |
| 18.3087% | |
| 17.2019% | |
| 16.8236% | |
| 15.9782% | |
| 15.8471% | |
| 12.8494% | |
| 12.5722% | |
| 11.2251% | |
| 11.2087% | |
| 11.5625% | |
| 11.6892% | |
| 11.2088% | |
| 9.5699% | |
| 9.5801% |